Skip to search formSkip to main contentSkip to account menu

GSK 461364

Known as: GSK-461364, GSK461364, Polo-like Kinase 1 Inhibitor GSK461364 
A small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively… 
National Institutes of Health

Related topics

Related topics

6 relations
Aurora Kinase AInhibition of Cell ProliferationPLK1 protein, humanSignal Transduction Inhibition

Broader (2)

BenzimidazolesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Polo‐like kinase 1 inhibition results in misaligned chromosomes and aberrant spindles in porcine oocytes during the first meiotic division
  • Y. LiaoD. Lin S. Ju
  • Reproduction in domestic animals = Zuchthygiene
  • 2018
  • Corpus ID: 32417169
Polo-like kinase 1 (Plk1), a type of serine/threonine protein kinase, has been implicated in various functions in the regulation… 
2017
2017
Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
BACKGROUND Medulloblastoma (MB) is one of most frequent malignant tumors that affect children. Despite the relatively good… 
2016
2016
Effect of AKT3 expression on MYC‐ and caspase‐8‐dependent apoptosis caused by polo‐like kinase inhibitors in HCT 116 cells
Polo‐like kinase (PLK) is a cell‐cycle regulator that is overexpressed in several cancer cell types. Polo‐like kinase is… 
2015
2015
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments
Polo-like kinase 1 (PLK1), a key regulator of mitosis, is often overexpressed in childhood cancers and is associated with poor… 
2015
2015
Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP‐binding Domain or Polo‐box Domain
The expression of polo‐like kinase 1 (Plk1) correlates with malignancy and is thus recognized as a target for cancer therapy. In… 
2011
2011
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1)
RNAi screening holds the promise of systemizing the search for combination therapeutic strategies. Here we performed a pooled… 
2008
2008
431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
2007
2007
Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models
5388 Human Polo-like kinase 1 (Plk1) is essential for mitosis and regulates multiple stages of mitotic progression. In cancer… 
2007
2007
Biochemical characterization of GSK461364: A novel, potent, and selective inhibitor of Polo-like kinase-1 (Plk1)
3257 Polo-like kinases are evolutionarily conserved ser/thr kinases that play critical roles in regulating mitosis in diverse… 
2007
2007
Identification of GSK461364, a novel small molecule polo-like kinase 1 inhibitor for the treatment of cancer
4171 Polo-like kinase 1 (Plk1) plays an important role in the entry to, progression through, and exit from mitosis. The multiple… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)